Furthermore, HER2 and estrogen receptor 1 gene (ESR1) mutations are mutually exclusive in primary breast cancer, suggesting that HER2 mutations are independent predictive and prognostic markers in estrogen receptor (ER)-positive MBC[11,12,16]. This evidence concerns the gene ERBB2 and breast cancer.